Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Cordlife Group

BST:3DC
Snowflake Description

Undervalued with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3DC
BST
SGD81M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, and internationally. The last earnings update was 32 days ago. More info.


Add to Portfolio Compare Print
  • Cordlife Group has significant price volatility in the past 3 months.
3DC Share Price and Events
7 Day Returns
-32.5%
BST:3DC
8.4%
DE Healthcare
9.9%
DE Market
1 Year Returns
-27.7%
BST:3DC
-25.6%
DE Healthcare
-17.5%
DE Market
3DC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cordlife Group (3DC) -32.5% -24.3% -40.9% -27.7% -76.2% -78.2%
DE Healthcare 8.4% -16.2% -21.1% -25.6% -43.3% -32%
DE Market 9.9% -16.6% -24.8% -17.5% -24.5% -28.1%
1 Year Return vs Industry and Market
  • 3DC underperformed the Healthcare industry which returned -25.6% over the past year.
  • 3DC underperformed the Market in Germany which returned -17.5% over the past year.
Price Volatility
3DC
Industry
5yr Volatility vs Market

3DC Value

 Is Cordlife Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cordlife Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cordlife Group.

BST:3DC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 4%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:3DC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.66
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.657 (1 + (1- 17%) (8.35%))
0.801
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.801 * 5.44%)
3.97%

Discounted Cash Flow Calculation for BST:3DC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cordlife Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

BST:3DC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (SGD, Millions) Source Present Value
Discounted (@ 3.97%)
2020 13.16 Est @ 33.23% 12.66
2021 16.20 Est @ 23.15% 14.99
2022 18.81 Est @ 16.09% 16.74
2023 20.91 Est @ 11.14% 17.89
2024 22.51 Est @ 7.68% 18.53
2025 23.70 Est @ 5.26% 18.76
2026 24.54 Est @ 3.57% 18.69
2027 25.13 Est @ 2.38% 18.40
2028 25.51 Est @ 1.55% 17.98
2029 25.76 Est @ 0.97% 17.46
Present value of next 10 years cash flows SGD172.00
BST:3DC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= SGD25.76 × (1 + -0.39%) ÷ (3.97% – -0.39%)
SGD588.90
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= SGD588.90 ÷ (1 + 3.97%)10
SGD399.09
BST:3DC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= SGD172.00 + SGD399.09
SGD571.09
Equity Value per Share
(SGD)
= Total value / Shares Outstanding
= SGD571.09 / 254.01
SGD2.25
BST:3DC Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:3DC represents 0.50625x of SGX:P8A
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.50625x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (SGD) x Listing Adjustment Factor
= SGD 2.25 x 0.50625
€1.14
Value per share (EUR) From above. €1.14
Current discount Discount to share price of €0.16
= -1 x (€0.16 - €1.14) / €1.14
85.8%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Cordlife Group is available for.
Intrinsic value
>50%
Share price is €0.16 vs Future cash flow value of €1.14
Current Discount Checks
For Cordlife Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Cordlife Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Cordlife Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cordlife Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cordlife Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:3DC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in SGD SGD0.03
SGX:P8A Share Price ** SGX (2020-03-31) in SGD SGD0.32
Germany Healthcare Industry PE Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 27.51x
Germany Market PE Ratio Median Figure of 399 Publicly-Listed Companies 16.31x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cordlife Group.

BST:3DC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= SGX:P8A Share Price ÷ EPS (both in SGD)

= 0.32 ÷ 0.03

12.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cordlife Group is good value based on earnings compared to the DE Healthcare industry average.
  • Cordlife Group is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does Cordlife Group's expected growth come at a high price?
Raw Data
BST:3DC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 12.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Healthcare Industry PEG Ratio Median Figure of 7 Publicly-Listed Healthcare Companies 1.22x
Germany Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.18x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cordlife Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cordlife Group's assets?
Raw Data
BST:3DC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in SGD SGD0.51
SGX:P8A Share Price * SGX (2020-03-31) in SGD SGD0.32
Germany Healthcare Industry PB Ratio Median Figure of 14 Publicly-Listed Healthcare Companies 1.13x
Germany Market PB Ratio Median Figure of 571 Publicly-Listed Companies 1.43x
BST:3DC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= SGX:P8A Share Price ÷ Book Value per Share (both in SGD)

= 0.32 ÷ 0.51

0.63x

* Primary Listing of Cordlife Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cordlife Group is good value based on assets compared to the DE Healthcare industry average.
X
Value checks
We assess Cordlife Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Cordlife Group has a total score of 5/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

3DC Future Performance

 How is Cordlife Group expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cordlife Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.4%
Expected Healthcare industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cordlife Group expected to grow at an attractive rate?
  • Unable to compare Cordlife Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Cordlife Group's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Cordlife Group's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:3DC Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 9.4%
Germany Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 5.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:3DC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in SGD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:3DC Past Financials Data
Date (Data in SGD Millions) Revenue Cash Flow Net Income *
2019-12-31 62 12 6
2019-09-30 69 8 5
2019-06-30 69 5 4
2019-03-31 69 6 4
2018-12-31 70 7 4
2018-06-30 68 9 3
2018-03-31 67 8 3
2017-12-31 63 6 2
2017-09-30 62 4 -1
2017-06-30 60 4 -3
2017-03-31 60 0 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Cordlife Group is high growth as no earnings estimate data is available.
  • Unable to determine if Cordlife Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:3DC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Cordlife Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:3DC Past Financials Data
Date (Data in SGD Millions) EPS *
2019-12-31 0.03
2019-09-30 0.02
2019-06-30 0.02
2019-03-31 0.02
2018-12-31 0.01
2018-06-30 0.01
2018-03-31 0.01
2017-12-31 0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Cordlife Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine whether Cordlife Group is trading at Cordlife Group'san attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  2. Cordlife Group's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. Cordlife Group's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Cordlife Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cordlife Group has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

3DC Past Performance

  How has Cordlife Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cordlife Group's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cordlife Group's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Cordlife Group's 1-year earnings growth exceeds its 5-year average (75.4% vs -48.1%)
  • Cordlife Group's earnings growth has exceeded the DE Healthcare industry average in the past year (75.4% vs 26%).
Earnings and Revenue History
Cordlife Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cordlife Group Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:3DC Past Revenue, Cash Flow and Net Income Data
Date (Data in SGD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 61.58 6.47 43.13
2019-09-30 69.24 4.51 42.96
2019-06-30 68.84 4.00 43.00
2019-03-31 69.25 3.97 43.46
2018-12-31 70.00 3.69 44.13
2018-06-30 68.31 3.27 43.48
2018-03-31 66.54 2.91 42.00
2017-12-31 63.06 1.66 40.97
2017-09-30 61.90 -1.35 40.20
2017-06-30 59.96 -2.57 39.16
2017-03-31 59.71 -5.75 40.61
2016-12-31 60.42 -7.40 39.67
2016-09-30 59.74 4.50 39.06
2016-06-30 59.63 12.33 37.88
2016-03-31 59.82 35.64 37.34
2015-12-31 59.15 55.82 36.01
2015-09-30 58.87 43.18 35.67
2015-06-30 57.58 32.46 34.91
2015-03-31 55.60 27.74 32.10
2014-12-31 53.14 11.13 30.76
2014-09-30 51.02 18.39 28.52
2014-06-30 49.09 30.52 27.12
2014-03-31 44.90 18.25 24.97
2013-12-31 40.29 17.95 22.56
2013-09-30 37.39 19.35 20.45
2013-06-30 34.70 13.48 17.77

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Cordlife Group has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • It is difficult to establish if Cordlife Group has efficiently used its assets last year compared to the DE Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cordlife Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cordlife Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cordlife Group has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

3DC Health

 How is Cordlife Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cordlife Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cordlife Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cordlife Group's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cordlife Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 19.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cordlife Group Company Filings, last reported 3 months ago.

BST:3DC Past Debt and Equity Data
Date (Data in SGD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 129.27 4.30 37.69
2019-09-30 127.08 4.38 40.57
2019-06-30 118.27 4.45 47.15
2019-03-31 119.06 4.53 47.95
2018-12-31 121.34 4.61 43.98
2018-06-30 121.49 5.44 48.78
2018-03-31 120.86 6.68 43.63
2017-12-31 119.62 6.75 52.85
2017-09-30 119.17 7.50 53.88
2017-06-30 125.33 8.73 61.05
2017-03-31 123.84 8.80 59.26
2016-12-31 124.78 8.88 59.40
2016-09-30 132.06 77.21 136.06
2016-06-30 132.76 78.27 138.41
2016-03-31 129.03 78.19 139.45
2015-12-31 127.22 82.79 158.19
2015-09-30 169.06 129.49 90.16
2015-06-30 161.95 129.30 30.19
2015-03-31 143.72 128.72 33.78
2014-12-31 125.38 128.80 34.42
2014-09-30 131.28 12.76 37.14
2014-06-30 141.29 12.85 45.74
2014-03-31 128.60 12.91 33.98
2013-12-31 130.29 12.98 37.01
2013-09-30 85.52 6.14 8.74
2013-06-30 77.56 6.20 12.08
  • Cordlife Group's level of debt (3.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (102.6% vs 3.3% today).
  • Debt is well covered by operating cash flow (270.1%, greater than 20% of total debt).
  • Unable to confirm if the interest payments on Cordlife Group's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Cordlife Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cordlife Group has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

3DC Dividends

 What is Cordlife Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
3.13%
Current annual income from Cordlife Group dividends.
If you bought €2,000 of Cordlife Group shares you are expected to receive €63 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Cordlife Group's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.68%).
  • Cordlife Group's dividend is below the markets top 25% of dividend payers in Germany (4.97%).
Upcoming dividend payment

Purchase Cordlife Group before the 'Ex-dividend' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:3DC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.8%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:3DC Past Annualized Dividends Data
Date (Data in SGD) Dividend per share (annual) Avg. Yield (%)
2020-02-28 0.010 3.006
2019-04-10 0.008 1.740
2018-08-14 0.008 1.831
2017-10-12 0.005 0.672
2017-08-29 0.005 0.611
2017-05-12 0.000 0.000
2017-02-13 0.000 0.000
2016-11-11 0.000 0.000
2016-10-12 0.000 0.000
2016-08-26 0.000 0.000
2016-05-11 0.000 0.000
2016-02-12 0.000 0.000
2015-09-30 0.020 1.429
2015-08-27 0.020 1.549
2015-05-11 0.020 1.731
2015-02-13 0.020 1.908
2014-08-25 0.020 2.048
2014-05-12 0.020 1.707
2014-02-11 0.020 1.693
2013-08-27 0.020 1.624
2013-05-13 0.020 1.956
2013-02-14 0.020 2.985
2012-10-04 0.018 3.225
2012-08-24 0.018 3.288
2012-05-14 0.018 3.753

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cordlife Group has been paying a dividend for less than 10 years and during this time payments have been volatile (annual drop of over 20%).
  • Cordlife Group has only been paying a dividend for 8 years, and since then dividends per share have fallen.
Current Payout to shareholders
What portion of Cordlife Group's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (2.6x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Cordlife Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cordlife Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cordlife Group has a total score of 2/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

3DC Management

 What is the CEO of Cordlife Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Poh Tan
AGE 57
TENURE AS CEO 1 years
CEO Bio

Ms. Poh Lan Tan has been Group Chief Executive Officer and Executive Director at Cordlife Group Limited since February 28, 2019 and served as its Group Chief Operating Officer since April 12, 2016 until 2019. Ms. Tan served as the Chief Executive Officer of Gleneagles Hospital of Parkway Holdings Ltd. since September 1, 2008. Ms. Tan served as Chief Executive Officer of East Shore Hospital since March 1, 2007. She is responsible for the general management and operations of the hospital. Ms. Tan joined Mount Elizabeth Hospital in March 1991 and worked as an Assistant General Manager of Mount Elizabeth Hospital. She has been a Non Independent & Non Executive Director of Stemlife Berhad since May 26, 2016. She served as an Executive Director of Cordlife Group Limited since April 12, 2016 until October 28, 2016. Ms. Tan graduated with Bachelor of Occupational Therapy from University of Queensland, Australia and holds an MBA from University of Singapore.

CEO Compensation
  • Insufficient data for Poh to compare compensation growth.
  • Insufficient data for Poh to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Cordlife Group management team in years:

3
Average Tenure
43
Average Age
  • The tenure for the Cordlife Group management team is about average.
Management Team

Poh Tan

TITLE
Group CEO & Executive Director
AGE
57
TENURE
1 yrs

Boon Yong Choo

TITLE
Group Chief Financial Officer
TENURE
3 yrs

Huiying Tan

TITLE
Group Director of Quality & Operations
AGE
37
TENURE
5.7 yrs

Andrew Ekaputra

TITLE
Group Technical Director

Siew Koon Ang

TITLE
Company Secretary

Hnin Yi Thet

TITLE
Group Finance Director
AGE
43
TENURE
3 yrs
Board of Directors Tenure

Average tenure and age of the Cordlife Group board of directors in years:

1.2
Average Tenure
56
Average Age
  • The average tenure for the Cordlife Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Goh Jin Hian

TITLE
Independent Chairman
COMPENSATION
SGD125K
AGE
50
TENURE
1.8 yrs

Poh Tan

TITLE
Group CEO & Executive Director
AGE
57
TENURE
1 yrs

Choon Hou Ho

TITLE
Independent Vice Chairman
COMPENSATION
SGD150K
AGE
47
TENURE
3.3 yrs

Joseph Wong

TITLE
Independent Director
COMPENSATION
SGD125K
AGE
64
TENURE
5.4 yrs

Hwee Yeo

TITLE
Independent Director
COMPENSATION
SGD51K
AGE
62
TENURE
1.8 yrs

Chi Wah Fong

TITLE
Non-Independent Non-Executive Director
AGE
56
TENURE
1.2 yrs

Lin Wang

TITLE
Non-Independent Non-Executive Director
TENURE
0.3 yrs

Ling Yun Zhai

TITLE
Non-Independent Non-Executive Director
AGE
45
TENURE
0.3 yrs

Chien Chang

TITLE
Non-Independent Non-Executive Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Jul 19 Sell FIL Limited Company 10. Jul 19 10. Jul 19 -16,880,000 €0.34 €-5,801,038
11. Jul 19 Buy Kwok Lung Hon Individual 10. Jul 19 10. Jul 19 16,880,000 €0.39 €6,629,756
X
Management checks
We assess Cordlife Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cordlife Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

3DC News

Simply Wall St News

3DC Company Info

Description

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, Indonesia, Myanmar, Vietnam, the Philippines, and internationally. It operates through two segments, Banking and Diagnostics. The company provides cord blood, cord lining, and cord tissue banking services comprising processing and storage of stem cells; and newborn screening services for metabolic disorders. It also offers management and property investment services. The company was formerly known as Cordlife Pte Ltd and changed its name to Cordlife Group Limited in 2011. Cordlife Group Limited was founded in 2001 and is headquartered in Singapore.

Details
Name: Cordlife Group Limited
3DC
Exchange: BST
Founded: 2001
SGD52,021,284
254,007,494
Website: http://www.cordlife.com
Address: Cordlife Group Limited
A’Posh Bizhub,
No. 06-01 / 09, 1 Yishun Industrial Street 1,
Singapore,
768160,
Singapore
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
SGX P8A Ordinary Shares Singapore Exchange SG SGD 29. Mar 2012
OTCPK CLIF.F Ordinary Shares Pink Sheets LLC US USD 29. Mar 2012
BST 3DC Ordinary Shares Boerse-Stuttgart DE EUR 29. Mar 2012
Number of employees
Current staff
Staff numbers
0
Cordlife Group employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 22:55
End of day share price update: 2020/03/31 00:00
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.